Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abrey, L. E.
Right arrow Articles by Yahalom, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abrey, L. E.
Right arrow Articles by Yahalom, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 16, 859-863, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Long-term survival in primary CNS lymphoma

LE Abrey, LM DeAngelis and J Yahalom
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

PURPOSE: We have previously reported on 31 patients with primary CNS lymphoma (PCNSL) treated between 1986 and 1992 with methotrexate (MTX), cranial radiotherapy (RT), and high-dose cytarabine who remained free of disease longer than historical controls. PATIENTS AND METHODS: We performed a follow-up analysis of our original cohort and now report their long-term survival and late treatment-related toxicity. RESULTS: The median cause-specific survival was 42 months, with a five-year survival of 22.3% compared with 3% to 4% in historical controls treated with RT alone. Age less than 50 years at diagnosis was a significant prognostic factor for survival (P = .01). Median disease-free survival was 40.3 months; 15 patients relapsed, all but one in the CNS. Late treatment-related toxicity was observed in nearly one third of patients and those more than 60 years of age were at substantially higher risk (P < .0001). CONCLUSION: Combined modality therapy for PCNSL has improved survival, but relapse is common and late neurologic toxicity is a significant complication. Although this approach is highly effective for younger patients, efficacious but less neurotoxic regimens need to be developed for older patients.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
L. Angelov, N. D. Doolittle, D. F. Kraemer, T. Siegal, G. H. Barnett, D. M. Peereboom, G. Stevens, J. McGregor, K. Jahnke, C. A. Lacy, et al.
Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience
J. Clin. Oncol., July 20, 2009; 27(21): 3503 - 3509.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Sierra del Rio, A. Rousseau, C. Soussain, D. Ricard, and K. Hoang-Xuan
Primary CNS Lymphoma in Immunocompetent Patients
Oncologist, May 1, 2009; 14(5): 526 - 539.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Neurological DisordersHome page
U. Schlegel
Review: Primary CNS lymphoma
Therapeutic Advances in Neurological Disorders, March 1, 2009; 2(2): 93 - 104.
[Abstract] [PDF]

Home page
 Ann OncolHome page
G. Illerhaus, R. Marks, F. Muller, G. Ihorst, F. Feuerhake, M. Deckert, C. Ostertag, and J. Finke
High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study
Ann. Onc., February 1, 2009; 20(2): 319 - 325.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
M. Linnebank, S. Moskau, A. Jurgens, M. Simon, A. Semmler, K. Orlopp, A. Glasmacher, C. Bangard, M. Vogt-Schaden, H. Urbach, et al.
Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma
Neuro-oncol, January 1, 2009; 11(1): 2 - 8.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
J.-J. Zhu, E. R. Gerstner, D. A. Engler, M. M. Mrugala, W. Nugent, K. Nierenberg, F. H. Hochberg, R. A. Betensky, and T. T. Batchelor
High-dose methotrexate for elderly patients with primary CNS lymphoma
Neuro-oncol, January 1, 2009; 11(2): 211 - 215.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
K. Jahnke, L. L. Muldoon, C. G. Varallyay, S. J. Lewin, R. D. Brown, D. F. Kraemer, C. Soussain, and E. A. Neuwelt
Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma
Neuro-oncol, January 1, 2009; 11(5): 503 - 513.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
M. J.B. Taphoorn
Neurocognitive Effects of Radiotherapy
ASCO Educational Book, January 1, 2009; 2009(1): 90 - 93.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
J.-F. Mineo, A. Scheffer, C. Karkoutly, L. Nouvel, O. Kerdraon, J. Trauet, A. Bordron, J.-P. Dessaint, M. Labalette, C. Berthou, et al.
Using Human CD20-Transfected Murine Lymphomatous B Cells to Evaluate the Efficacy of Intravitreal and Intracerebral Rituximab Injections in Mice
Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 4738 - 4745.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
L. Fischer, P. Martus, M. Weller, H. A. Klasen, B. Rohden, A. Roth, B. Storek, M. Hummel, T. Nagele, E. Thiel, et al.
Meningeal dissemination in primary CNS lymphoma: Prospective evaluation of 282 patients
Neurology, September 30, 2008; 71(14): 1102 - 1108.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
R. Yamanaka, K. Morii, Y. Shinbo, J. Homma, M. Sano, N. Tsuchiya, N. Yajima, T. Tamura, H. Hondoh, H. Takahashi, et al.
Results of Treatment of 112 Cases of Primary CNS Lymphoma
Jpn. J. Clin. Oncol., May 1, 2008; 38(5): 373 - 380.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. D. Shah, J. Yahalom, D. D. Correa, R. K. Lai, J. J. Raizer, D. Schiff, R. LaRocca, B. Grant, L. M. DeAngelis, and L. E. Abrey
Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma
J. Clin. Oncol., October 20, 2007; 25(30): 4730 - 4735.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. F. Hottinger, L. M. DeAngelis, J. Yahalom, and L. E. Abrey
Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma
Neurology, September 11, 2007; 69(11): 1178 - 1182.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Correa, L Maron, H Harder, M Klein, C. Armstrong, P Calabrese, J. Bromberg, L. Abrey, T. Batchelor, and D Schiff
Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines
Ann. Onc., July 1, 2007; 18(7): 1145 - 1151.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
P. Kiewe, C. Loddenkemper, I. Anagnostopoulos, M. Reinwald, E. Thiel, and A. Korfel
High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma
Neuro-oncol, April 1, 2007; 9(2): 96 - 102.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M Montemurro, T Kiefer, F Schuler, H. Al-Ali, H-H Wolf, R Herbst, A Haas, K Helke, A Theilig, C Lotze, et al.
Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study
Ann. Onc., April 1, 2007; 18(4): 665 - 671.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. T. Gavrilovic, A. Hormigo, J. Yahalom, L. M. DeAngelis, and L. E. Abrey
Long-Term Follow-Up of High-Dose Methotrexate-Based Therapy With and Without Whole Brain Irradiation for Newly Diagnosed Primary CNS Lymphoma
J. Clin. Oncol., October 1, 2006; 24(28): 4570 - 4574.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Illerhaus, R. Marks, G. Ihorst, R. Guttenberger, C. Ostertag, G. Derigs, N. Frickhofen, F. Feuerhake, B. Volk, and J. Finke
High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line Treatment of Primary CNS Lymphoma
J. Clin. Oncol., August 20, 2006; 24(24): 3865 - 3870.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Fischer, E. Thiel, H.-A. Klasen, J. Birkmann, K. Jahnke, P. Martus, and A. Korfel
Prospective trial on topotecan salvage therapy in primary CNS lymphoma
Ann. Onc., July 1, 2006; 17(7): 1141 - 1145.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. L. Rubenstein, J. Fridlyand, A. Shen, K. Aldape, D. Ginzinger, T. Batchelor, P. Treseler, M. Berger, M. McDermott, M. Prados, et al.
Gene expression and angiotropism in primary CNS lymphoma
Blood, May 1, 2006; 107(9): 3716 - 3723.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Batchelor and J. S. Loeffler
Primary CNS Lymphoma
J. Clin. Oncol., March 10, 2006; 24(8): 1281 - 1288.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
C. S. Ha, L. J. Medeiros, C. Charnsangavej, M. Crump, and M. K. Gospodarowicz
Oncodiagnosis Panel: 2004: Lymphoma
RadioGraphics, March 1, 2006; 26(2): 607 - 620.
[Full Text] [PDF]

Home page
 IOVSHome page
S. E. Coupland, C. Loddenkemper, J. R. Smith, R. M. Braziel, F. Charlotte, I. Anagnostopoulos, and H. Stein
Expression of Immunoglobulin Transcription Factors in Primary Intraocular Lymphoma and Primary Central Nervous System Lymphoma
Invest. Ophthalmol. Vis. Sci., November 1, 2005; 46(11): 3957 - 3964.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
A. M. P. Omuro, L. S. Ben-Porat, K. S. Panageas, A. K. Kim, D. D. Correa, J. Yahalom, L. M. DeAngelis, and L. E. Abrey
Delayed Neurotoxicity in Primary Central Nervous System Lymphoma
Arch Neurol, October 1, 2005; 62(10): 1595 - 1600.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
K. Fliessbach, C. Helmstaedter, H. Urbach, A. Althaus, H. Pels, M. Linnebank, A. Juergens, A. Glasmacher, I. G. Schmidt-Wolf, T. Klockgether, et al.
Neuropsychological outcome after chemotherapy for primary CNS lymphoma: A prospective study
Neurology, April 12, 2005; 64(7): 1184 - 1188.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. N. Shenkier, J.-Y. Blay, B. P. O'Neill, P. Poortmans, E. Thiel, K. Jahnke, L. E. Abrey, E. Neuwelt, R. Tsang, T. Batchelor, et al.
Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group
J. Clin. Oncol., April 1, 2005; 23(10): 2233 - 2239.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. L. Nguyen, A. Chakravarti, D. M. Finkelstein, F. H. Hochberg, T. T. Batchelor, and J. S. Loeffler
Results of Whole-Brain Radiation As Salvage of Methotrexate Failure for Immunocompetent Patients With Primary CNS Lymphoma
J. Clin. Oncol., March 1, 2005; 23(7): 1507 - 1513.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
E. A. Neuwelt, P. E. Guastadisegni, P. Varallyay, and N. D. Doolittle
Imaging Changes and Cognitive Outcome in Primary CNS Lymphoma after Enhanced Chemotherapy Delivery
AJNR Am. J. Neuroradiol., February 1, 2005; 26(2): 258 - 265.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
T. T. Batchelor, B. R. Buchbinder, and N. L. Harris
Case 1-2005 - A 35-Year-Old Woman with Difficulty Walking, Headache, and Nausea
N. Engl. J. Med., January 13, 2005; 352(2): 185 - 194.
[Full Text] [PDF]

Home page
 NeurologyHome page
A. M.P. Omuro, L. M. DeAngelis, J. Yahalom, and L. E. Abrey
Chemoradiotherapy for primary CNS lymphoma: An intent-to-treat analysis with complete follow-up
Neurology, January 11, 2005; 64(1): 69 - 74.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Hoang-Xuan and J.Y. Delattre
In Reply:
J. Clin. Oncol., March 15, 2004; 22(6): 1167 - 1168.
[Full Text] [PDF]

Home page
 JCOHome page
M. Reni and A. J.M. Ferreri
Is Withdrawal of Consolidation Radiotherapy an Evidence-Based Strategy in Primary Central Nervous System Lymphomas?
J. Clin. Oncol., March 15, 2004; 22(6): 1165 - 1167.
[Full Text] [PDF]

Home page
 NeurologyHome page
D. D. Correa, L. M. DeAngelis, W. Shi, H. Thaler, A. Glass, and L. E. Abrey
Cognitive functions in survivors of primary central nervous system lymphoma
Neurology, February 24, 2004; 62(4): 548 - 555.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Pels, I. G.H. Schmidt-Wolf, A. Glasmacher, H. Schulz, A. Engert, V. Diehl, A. Zellner, G. Schackert, H. Reichmann, F. Kroschinsky, et al.
Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy
J. Clin. Oncol., December 15, 2003; 21(24): 4489 - 4495.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. M. DeAngelis
Primary Central Nervous System Lymphoma: A Curable Brain Tumor
J. Clin. Oncol., December 15, 2003; 21(24): 4471 - 4473.
[Full Text] [PDF]

Home page
 JCOHome page
L. E. Abrey, C. H. Moskowitz, W. P. Mason, M. Crump, D. Stewart, P. Forsyth, N. Paleologos, D. D. Correa, N. D. Anderson, D. Caron, et al.
Intensive Methotrexate and Cytarabine Followed by High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Newly Diagnosed Primary CNS Lymphoma: An Intent-to-Treat Analysis
J. Clin. Oncol., November 15, 2003; 21(22): 4151 - 4156.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. S. Lima, E. B. Leite, R. P. Fonseca, and A. S. Fernandes Jr
Patients Presenting With CNS Lesions: CASE 1. PRIMARY LOW-GRADE MUCOSA-ASSOCIATED B-CELL LYMPHOMA OF THE DURA
J. Clin. Oncol., November 1, 2003; 21(21): 4058 - 4060.
[Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
H. Ishikawa, M. Hasegawa, Y. Tamaki, K. Hayakawa, T. Akimoto, H. Sakurai, N. Mitsuhashi, H. Niibe, M. Tamura, and T. Nakano
Comparable Outcomes of Radiation Therapy without High-dose Methotrexate for Patients with Primary Central Nervous System Lymphoma
Jpn. J. Clin. Oncol., September 1, 2003; 33(9): 443 - 449.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Hoang-Xuan, L. Taillandier, O. Chinot, P. Soubeyran, U. Bogdhan, J. Hildebrand, M. Frenay, N. De Beule, J.Y. Delattre, and B. Baron
Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group
J. Clin. Oncol., July 15, 2003; 21(14): 2726 - 2731.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J.M. Ferreri, L. E. Abrey, J.-Y. Blay, B. Borisch, J. Hochman, E. A. Neuwelt, J. Yahalom, E. Zucca, F. Cavalli, J. Armitage, et al.
Summary Statement on Primary Central Nervous System Lymphomas From the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002
J. Clin. Oncol., June 15, 2003; 21(12): 2407 - 2414.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
K. Fliessbach, H. Urbach, C. Helmstaedter, H. Pels, A. Glasmacher, J. A. Kraus, T. Klockgether, I. Schmidt-Wolf, and U. Schlegel
Cognitive Performance and Magnetic Resonance Imaging Findings After High-Dose Systemic and Intraventricular Chemotherapy for Primary Central Nervous System Lymphoma
Arch Neurol, April 1, 2003; 60(4): 563 - 568.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Roychowdhury, R. Peng, R. A. Baiocchi, D. Bhatt, S. Vourganti, J. Grecula, N. Gupta, C. F. Eisenbeis, G. J. Nuovo, W. Yang, et al.
Experimental Treatment of Epstein-Barr Virus-associated Primary Central Nervous System Lymphoma
Cancer Res., March 1, 2003; 63(5): 965 - 971.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. M. DeAngelis, W. Seiferheld, S. C. Schold, B. Fisher, and C. J. Schultz
Combination Chemotherapy and Radiotherapy for Primary Central Nervous System Lymphoma: Radiation Therapy Oncology Group Study 93-10
J. Clin. Oncol., December 15, 2002; 20(24): 4643 - 4648.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A multicenter study of treatment of primary CNS lymphoma
Neurology, May 28, 2002; 58(10): 1513 - 1520.


Home page
 NeurologyHome page
U. Herrlinger, W. Kuker, M. Platten, J. Dichgans, and M. Weller
First-line therapy with temozolomide induces regression of primary CNS lymphoma
Neurology, May 28, 2002; 58(10): 1573 - 1574.
[Full Text] [PDF]

Home page
 JCOHome page
E. M. Bessell, A. Lopez-Guillermo, S. Villa, E. Verger, B. Nomdedeu, J. Petit, P. Byrne, E. Montserrat, and F. Graus
Importance of Radiotherapy in the Outcome of Patients With Primary CNS Lymphoma: An Analysis of the CHOD/BVAM Regimen Followed by Two Different Radiotherapy Treatments
J. Clin. Oncol., January 1, 2002; 20(1): 231 - 236.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
A. Lister, L. E. Abrey, and J. T. Sandlund
Central Nervous System Lymphoma
Hematology, January 1, 2002; 2002(1): 283 - 296.
[Abstract] [Full Text]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
U Schlegel, H Pels, A Glasmacher, R Kleinschmidt, I Schmidt-Wolf, C Helmstaedter, K Fliessbach, M Deckert, D Van Roost, R Fimmers, et al.
Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study
J. Neurol. Neurosurg. Psychiatry, July 1, 2001; 71(1): 118 - 122.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. M. DeAngelis
Brain Tumors
N. Engl. J. Med., January 11, 2001; 344(2): 114 - 123.
[Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
N. D. Doolittle, C. P. Anderson, W. A. Bleyer, J. G. Cairncross, T. Cloughesy, S. L. Eck, P. Guastadisegni, W. A. Hall, L. L. Muldoon, S. J. Patel, et al.
Importance of dose intensity in neurooncology clinical trials: Summary Report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium
Neuro-oncol, January 1, 2001; 3(1): 46 - 54.
[Abstract] [PDF]

Home page
 JCOHome page
L. E. Abrey, J. Yahalom, and L. M. DeAngelis
Treatment for Primary CNS Lymphoma: The Next Step
J. Clin. Oncol., September 17, 2000; 18(17): 3144 - 3150.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
U. Herrlinger, W. Brugger, M. Bamberg, W. Kuker, J. Dichgans, and M. Weller
PCV salvage chemotherapy for recurrent primary CNS lymphoma
Neurology, April 25, 2000; 54(8): 1707 - 1708.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Reni, A. J. M. Ferreri, C. Landoni, and E. Villa
Salvage Therapy With Temozolomide in an Immunocompetent Patient With Primary Brain Lymphoma
J Natl Cancer Inst, April 5, 2000; 92(7): 575 - 576.
[Full Text] [PDF]

Home page
 JCOHome page
P. O’Brien, D. Roos, G. Pratt, K. Liew, M. Barton, M. Poulsen, I. Olver, and G. Trotter
Phase II Multicenter Study of Brief Single-Agent Methotrexate Followed by Irradiation in Primary CNS Lymphoma
J. Clin. Oncol., February 1, 2000; 18(3): 519 - 519.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
S. Ng, M. A. Rosenthal, D. Ashley, and L. Cher
High-dose methotrexate for primary CNS lymphoma in the elderly
Neuro-oncol, January 1, 2000; 2(1): 40 - 44.
[Abstract] [PDF]

Home page
 BloodHome page
A. R. Thompsett, D. W. Ellison, F. K. Stevenson, and D. Zhu
VH Gene Sequences From Primary Central Nervous System Lymphomas Indicate Derivation From Highly Mutated Germinal Center B Cells With Ongoing Mutational Activity
Blood, September 1, 1999; 94(5): 1738 - 1746.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
B. P. O'Neill, C.-H. Wang, J. R. O'Fallon, J. P. Colgan, J. D. Earle, R. L. Krigel, L. D. Brown, and W. J. McGinnis
The consequences of treatment and disease in patients with primary CNS non-Hodgkin's lymphoma: Cognitive function and performance status
Neuro-oncol, July 1, 1999; 1(3): 196 - 203.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
L. M DeANGELIS
Primary central nervous system lymphoma
J. Neurol. Neurosurg. Psychiatry, June 1, 1999; 66(6): 699 - 701.
[Full Text]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1998 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online